The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Solazyme's revenues will contract -3.2% and EPS will remain in the red.
The average estimate for revenue is $8.6 million. On the bottom line, the average EPS estimate is -$0.35.
Last quarter, Solazyme booked revenue of $13.5 million. GAAP reported sales were 83% higher than the prior-year quarter's $7.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at -$0.27. GAAP EPS were -$0.32 for Q2 against -$0.61 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 90.2%, 470 basis points worse than the prior-year quarter. Operating margin was -146.8%, 3,710 basis points better than the prior-year quarter. Net margin was -142.0%, 8,700 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $47.2 million. The average EPS estimate is -$1.23.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 335 members out of 356 rating the stock outperform, and 21 members rating it underperform. Among 66 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Solazyme a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solazyme is outperform, with an average price target of $18.50.
Are you missing a major story in the energy space? Read about "One Stock to Own Before Nat Gas Act 2011 Becomes Law." Click here for instant access to this free report.
- Add Solazyme to My Watchlist.